Pfizer Inc and BioNTech’s COVID-19 vaccine appeared to work against a key mutation in the highly transmissible new variants of the coronavirus discovered in the UK and South Africa, according to a laboratory study conducted by the US drugmaker.
The world is scrambling to contain the spread of the B.1.1.7 variant, despite travel bans, new lockdowns and a tightening quarantine measures in dozens of countries, amid concerns it could not only be more transmissible, but deadlier.
India suspended all incoming and outgoing international flights as well as domestic air travel in the last week of March 2020 as part of a lockdown to combat COVID-19. Flights to and from India have since been resumed in a phased manner with about two-dozen countries under "air bubbles."
UK bans flights from South Africa region, EU plans similar; Variant has a protein dramatically different to original; Epidemiologist wards travel cubs may be too late; Parts of Europe already battling record daily COVID cases.
This includes suspending the entry of travellers who were in these countries 14 days before coming to the UAE. Flight operations will continue to transport passengers from the UAE to these seven countries.
The United States, Australia, Brazil, Canada, UAE, Saudi Arabia and Oman became the latest countries on Friday to restrict travel from southern Africa, where a new Covid strain labelled a "variant of concern" has been discovered.
The World Health Organisation (WHO) warned that deciding the severity level of Omicron, identified first in South Africa, could take "days to several weeks" in the absence of information that its symptoms differed from those of other variants.
It could take "days to several weeks" to understand the level of severity of the variant, says the World Health Organisation (WHO), which flagged Omicron as a "variant of concern".
Infections have been reported in more than 210 countries and territories since the first cases were identified in December 2019.